32 patents
Utility
Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
19 Sep 23
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 25 Mar 21
Utility
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
22 Aug 23
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 9 Feb 22
Utility
Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
15 Aug 23
The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
Filed: 29 Oct 20
Utility
Heterocyclic adenosine receptor antagonists
8 Aug 23
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein.
Sunghoon Ma, Yong Wang, Wei Xu
Filed: 15 Mar 21
Utility
Compounds for the treatment of kinase-dependent disorders
25 Jul 23
Lynne Canne Bannen, Minna Bui, Faming Jiang, Yong Wang, Wei Xu
Filed: 25 Jan 19
Utility
Method of treating cancer
28 Mar 23
This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
David Smith, Maha Hussain
Filed: 18 Jun 20
Utility
MEK inhibitors and methods of their use
7 Mar 23
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof.
Naing Aay, Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Simona Costanzo, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Anagha Abhijit Joshi, Abigail R. Kennedy, Angie Inyoung Kim, Elena S. Koltun, Jean-Claire Limun Manalo, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang
Filed: 20 Apr 20
Utility
Cabozantinib dosage form and use in the treatment of cancer
31 Jan 23
This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.
Aaron Weitzman
Filed: 4 Apr 14
Utility
Compounds for the treatment of kinase-dependent disorders
3 Jan 23
Lynne Canne Bannen, Minna Bui, Faming Jiang, Kin Tso, Yong Wang, Wei Xu
Filed: 25 Jan 19
Utility
Liquid dosage forms to treat cancer
22 Nov 22
This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.
Khalid Shah, Gisela Schwab, Steven Lacy
Filed: 8 Jun 18
Utility
Method of treating cancer and bone cancer pain
22 Nov 22
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone.
Gisela Schwab, Dana T. Aftab
Filed: 11 Feb 20
Utility
Methods of using c-Met modulators
6 Sep 22
Dana T. Aftab, Thomas Mueller, Aaron Weitzman, Jaymes Holland
Filed: 2 Jul 20
Utility
Process for making compounds for use in the treatment of cancer
16 Aug 22
Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
Filed: 26 Aug 20
Utility
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
22 Mar 22
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 26 May 18
Utility
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
22 Feb 22
This disclosure relates to the crystalline fumarate salt of (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.
Adrian St. Clair Brown
Filed: 17 Jan 20
Utility
Combinations of cabozantinib and atezolizumab to treat cancer
14 Dec 21
This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
Gisela Schwab, Christian Scheffold, Colin Hessel
Filed: 19 Jan 18
Utility
Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
12 Oct 21
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
Filed: 17 Apr 17
Utility
C-met modulator pharmaceutical compositions
21 Sep 21
Jo Ann Wilson, Khalid Shah
Filed: 20 Dec 19
Utility
Method of preparing fluorine-18 labeled Cabozantinib and its analogs
21 Sep 21
The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
Wei Xu, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
Filed: 31 Jul 15
Utility
C-met modulators and methods of use
21 Sep 21
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion.
Lynne Canne Bannen, Diva Sze-Ming Chan, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Vasu Jammalamadaka, Richard George Khoury, James William Leahy, Morrison B. Mac, Grace Mann, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Craig Stacy Takeuchi, Yong Wang, Wei Xu
Filed: 28 Aug 17